Stephen J. Gregson

Stephen J. Gregson

Auto-generated profile, based on publicly available information

Stephen J. Gregson

AstraZeneca Early Oncology, United Kingdom of Great Britain and Northern Ireland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KKKrista Kinneer
Krista Kinneer
JMJohn Meekin
John Meekin
ATArnaud C. Tiberghien
Arnaud C. Tiberghien
YTYu-Tzu Tai
Yu-Tzu Tai
SPSandrina Phipps
Sandrina Phipps
DTDavid A. Tice
David A. Tice
Purpose: Antibody–drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clinical use, and several are in development targeting solid and hematologic malignancies including multiple myeloma. Currently, there are no reliable biomarkers of activity for these ADCs other than presence of the targeted antigen. We observed that certain cell lines are innately resistant to such ADCs, and sought to uncover the underlying mechanism of resistance. Experimental Design: The expression of 43 lysosomal membrane target genes was evaluated in cell lines resistant to ADCs bearing the noncleavable linker, pyrrolobenzodiazepine payload SG3376, in vitro. The functional relevance of SLC46A3, a lysosomal transporter of noncleavable ADC catabolites whose expression uniquely correlated with SG3376 resistance, was assessed using EPHA2-, HER2-, and BCMA-targeted ADCs and isogenic cells overexpressing or genetically inactivated for SLC46A3. SLC46A3 expression was also examined in patient-derived xenograft and in vitro models of acquired T-DM1 resistance and multiple myeloma bone marrow samples by RT-PCR. Results: Loss of SLC46A3 expression was found to be a mechanism of innate and acquired resistance to ADCs bearing DM1 and SG3376. Sensitivity was restored in refractory lines upon introduction of SLC46A3, suggesting that expression of SLC46A3 may be more predictive of activity than target antigen levels alone. Interrogation of primary multiple myeloma samples indicated a range of SLC46A3 expression, including samples with undetectable levels like multiple myeloma cell lines resistant to BCMA-targeting DM1 and SG3376 ADCs. Conclusions: Our findings support SLC46A3 as a potential patient selection biomarker with immediate relevance to clinical trials involving these ADCs.

16 November 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SGStephen J. Gregson
Stephen J. Gregson
LMLuke A. Masterson
Luke A. Masterson
BWBinqing Wei
Binqing Wei
TPThomas Pillow
Thomas Pillow
SSSusan D. Spencer
Susan D. Spencer
PHPhilip W. Howard
Philip W. Howard

1 October 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SGStephen J. Gregson
Stephen J. Gregson
ABAllison M. Barrett
Allison M. Barrett
NPNeki V. Patel
Neki V. Patel
GKGyoung-Dong Kang
Gyoung-Dong Kang
DSDavide Schiavone
Davide Schiavone
PHPhilip W. Howard
Philip W. Howard

6 July 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
SGStephen J. Gregson
Stephen J. Gregson
KPKathryn Pugh
Kathryn Pugh
NPNeki Patel
Neki Patel
SAShameen Afif-Rider
Shameen Afif-Rider
BVBalakumar Vijayakrishnan
Balakumar Vijayakrishnan
PHPhilip W. Howard
Philip W. Howard
Antibody–drug conjugate (ADC) research has typically focused on the release of highly potent cytotoxic agents to achieve antitumor efficacy. However, recently approved ADCs trastuzumab deruxtecan and sacituzumab govitecan release lower-potency topoisomerase inhibitors. This has prompted interest in ADCs that release lower-potency cytotoxic drugs to potentially enhance therapeutic index and reduce unwanted toxicity. Pyrrolobenzodiazepine (PBD) dimer ADCs have been widely investigated in human clinical trials, which have focused on high-potency PBDs. In this study, we evaluated five ADCs that release the low-potency PBD dimer SG3650. The relatively low clogD for this agent facilitated higher drug-to-antibody ratio (DAR) conjugation without the need for antibody engineering or functionalization of the drug. The rank order of potency for DAR 2 site-specific ADCs (conjugated at the C239i position) matched the order for the corresponding free drugs in vitro. Despite free drug SG3650 being inactive in vivo, the DAR 2 ADCs derived from the corresponding drug-linker SG3584 showed antitumor efficacy in solid (anti-HER2) and hematologic (anti-CD22) xenograft models. Antitumor activity could be enhanced by conjugating SG3584 to trastuzumab at higher DARs of 4 and 8 and by adjusting dosing and schedule. Higher-DAR conjugates were stable and displayed good rat pharmacokinetic profiles as measured by ELISA and LC/MS-MS. A single intravenous dose of isotype control SG3584 DAR 2 ADC resulted in no mortality in rats or monkeys at doses of up to 25 and 30 mg/kg, respectively. These findings suggest that further investigations of low-potency PBD dimers in ADCs that target hematologic and solid tumors are warranted.

6 July 2026 in Synthesis
Verified
Journal Article
Open access
PKPhinyada Kankraisri
Phinyada Kankraisri
KSKhushal Siddiq
Khushal Siddiq
YMYao-Rui Ma
Yao-Rui Ma
JBJonathan Beadle
Jonathan Beadle
SGStephen J. Gregson
Stephen J. Gregson
CJChristopher Raymond Jones
Christopher Raymond Jones
We report herein an efficient transition-metal-free method for late-stage N-arylation at the C-terminus of oligopeptides. Exploiting intermediate O-benzyl hydroxamic acid derivatives, the transformation employs a range of aryne derivatives and is applicable to di-, tri-, and tetrapeptides, with subsequent selective N–O bond cleavage revealing the arylated parent oligopeptide. The method shows good tolerance of common protecting groups used in peptide synthesis and affords exclusive site-selectivity despite the presence of multiple N–H bonds.